Based on the available data, it can be concluded that the serological evaluations for CD with anti-tTG should be a part of the general workup in the asymptomatic patients with NAFLD when metabolic risk factors are not evident, and in the patients with steatohepatitis when other causes of the liver disease are excluded. This evidence concerns the gene TGM2 and liver disorder.